Epithelial-to-mesenchymal transition (EMT) is associated with poor prognosis and metastasis in hepatocellular carcinoma. We have previously demonstrated an in vivo model of liver cancer in which mesenchymal cells post-EMT demonstrate a high rate of invasive growth and metastasis. Here, we investigate the role of microRNA 200 (miR-200) family members and epigenetic modifications on the maintenance of mesenchymal/metastatic phenotype after EMT. Mesenchymal cells post-EMT demonstrates high levels of E-box repressors Zeb1 and Zeb2 and downregulation of four miR-200 family members (miR-200a, miR-200b, miR-200c and miR-429). In addition, DNA sequencing after bisulfite modification demonstrates that several CpG sites within the E-cadherin promoter are methylated in mesenchymal cells. In mesenchymal cells, forced expression of miR-200b results in a significant increase in E-cadherin and a reduction in cell migration/invasion. Despite these mesenchymal-to-epithelial transition (MET) changes in vitro, there is no significant change in metastatic potential after miR-200b upregulation in vivo. After the mesenchymal cells were treated with combination of DNA methyltransferase (DNMT) inhibitor and upregulation of miR-200b, invasive phenotype was significantly reduced and metastatic potential was eliminated. Direct targeting of E-cadherin with short hairpin RNA does not restore metastatic potential after DNMT inhibition and miR-200b re-expression. In addition, restoration of E-cadherin alone was unable to block metastatic potential in primary mesenchymal cells. In conclusion, targeting mesenchymal liver cancer cells with miR-200b and DNMT inhibitor reduces metastatic potential irrespective of E-cadherin expression. Thus, the broader differentiation and MET effects of DNMT inhibition and miR-200b must be considered in terms of rescuing metastatic potential.
INTRODUCTION
Hepatocellular carcinoma (HCC) remains the third leading cause of cancer-related death world-wide, 1 and the incidence of HCC related to Hepatitis C virus infection in the United States has increased 10 fold in the last decade. 2 Although the mortality of HCC patients is primarily related to metastatic disease, 3 the mechanisms underlying HCC invasion and metastasis are not well defined. 4 Metastasis is a multi-step process that requires fixed epithelial carcinomas to invade into surrounding tissue, survive the circulatory system and establish a distant colony. One proposed theory regarding metastasis is that epithelial carcinomas undergo epithelial-to-mesenchymal transition (EMT). 5, 6 After EMT, mesenchymal cells demonstrate decreased adhesion and increased motility, typically associated with the downregulation of E-cadherin, a component of the epithelial adherens junction. 7, 8 During EMT, a number of transcription factors, such as Snail, Slug, Zeb1, Zeb2, Twist1/2 and E12/E47, bind to the E-cadherin promoter and inhibit transcription. 7, 9, 10 EMT and downregulation of E-cadherin correlate with poor outcomes in HCC. [11] [12] [13] In a recent work, we demonstrated that epithelial HCC tumor cells acquired a mesenchymal phenotype via EMT in vivo.
14 In this model, mesenchymal cells post-EMT demonstrated invasive growth and established metastatic colonies compared with epithelial counterparts, which have slower local growth without significant invasion or metastasis.
miR-200 may facilitate breast cancer metastasis by enhancing colonization. 17, 18 The miR-200 family is highly conserved across different species, and consists of five members organized as two clusters, miRs200b/a/429 and miRs-200c/141, on chromosomes 1 and 12 in humans, and chromosomes 4 and 6 in mice. 19 In epithelial cells, miR-200 targets the 3 0 -UTR of Zeb1 and Zeb2 mRNA. 15, [20] [21] [22] In HCC, miR-200a is downregulated in tumor tissue compared with adjacent liver tissues. 23 In terms of survival, decreased miR-200b expression correlates with poor patient outcomes. 24 However, the precise role of the miR-200 family in the HCC progression and metastasis is not well defined.
In addition to transcriptional repressors, epigenetic modification is associated with EMT and metastatic disease. Specifically, the CpG island of E-cadherin promoter can be highly methylated in a variety of human cancers, such as colorectal, 25, 26 prostate, 27 cervical, 28 and breast cancer. 29 In HCC, E-cadherin promoter hypermethylation was associated with reduced E-cadherin expression and disease progression. 30 In this current study, we demonstrate that the miR-200 family was significantly downregulated in mesenchymal HCC cells compared with counterpart epithelial cells. Forced expression of miR-200b in mesenchymal cells results in Zeb1 and Zeb2 suppression, E-cadherin upregulation and the inhibition of tumor migration and invasion in vitro, but does not reduce metastatic potential in vivo. Further analysis demonstrates that the E-cadherin promoter is highly methylated in mesenchymal cells. For the first time, we demonstrate that the combination of a DNA methyltransferase (DNMT) inhibitor and restoration of miR-200b results in significant E-cadherin expression, MET, and complete loss of metastatic potential. However, this loss of metastatic potential was not overcome with direct targeting of E-cadherin.
RESULTS

The miR-200 family is downregulated in mesenchymal cells
The miR-200 family members are downregulated in many tumor cells with mesenchymal phenotype, and miR-200 levels inversely correlate with target genes, Zeb1 and Zeb2. 16 In a previous report, Pten À / À HCC epithelial cells acquired EMT after serial in vivo transplantation. The mesenchymal cells post-EMT demonstrate fibroblastoid morphology compared with cobble-stone morphology of the epithelial cells, and these mesenchymal cells are characterized by aggressive growth, invasion and metastasis in vivo.
14 In the mesenchymal cells, E-cadherin is significantly downregulated, and transcriptional repressors that drive EMT, Zeb1 and Zeb2, are significantly upregulated. 14 Further analysis demonstrates that four members of the miR-200 family (miR-200a, miR-200b, miR-200c and miR-429) are significantly downregulated in the mesenchymal cells (Figure 1a ). miR-205, which is not in the miR-200 family, but can target Zeb1 and Zeb2, 15 demonstrates no significant change after EMT (data not shown). Table 1 ). Histology of lung tissue confirms no significant difference between the number of mice with lung tumor metastatic nodules ( Figure 2f and Table 1 , miR-NC 22% vs miR200b 38%). These findings demonstrate that the restoration of miR-200b expression in mesenchymal cells is insufficient to inhibit lung metastasis.
E-cadherin promoter is highly methylated in mesenchymal cells In addition to transcriptional repressors, E-cadherin promoter methylation is a mechanism for suppression of E-cadherin transcription in HCC. 30, 31 Previous reports demonstrate that methylation of the CpG island in the E-cadherin promoter correlates to poor HCC clinical outcomes. 30, 32 We utilized DNA sequencing after bisulfite modification to demonstrate that 14 cytosine residues in the E-cadherin promoter CpG island are methylated in mesenchymal cells (Figure 3a and Supplementary Figure 6 ). This CpG methylation is reduced using DNMT inhibitor decitabine (Figure 3a) . Table 1 is compared with mesenchymal miR-NC, mesenchymal miR-NC þ vehicle, mesenchymal miR-NC þ decitabine and mesenchymal miR-200b groups). In addition, no mice (0%) demonstrate lung tumor nodules in the mesenchymal miR-200b and decitabine combination group, compared with 22-40% in the other treatment groups (Table 1 ). Abdominal organs (pancreas and colon) scored with extensive invasion ¼ 2, minor invasion ¼ 1, no invasion ¼ 0. The average score ¼ the total score/the number of animals. For example, in mesenchymal miR-NC group with total 9 mice: 6 mice with extensive pancreas invasion, and 6 mice with extensive colon invasion. The invasion score for this group will be (6 Â 2 þ 6 Â 2)/9 ¼ 2.7. 
Forced E-cadherin expression in mesenchymal cells is unable to reduce the metastatic potential As combination treatment of mesenchymal cells with miR-200b and decitabine results in synergistic upregulation of E-cadherin, we utilized an E-cadherin expression vector in mesenchymal cells to drive E-cadherin to levels above those in the original epithelial cells (Figure 5a) . We sought to test the hypothesis that focused E-cadherin upregulation reduces the metastatic potential of mesenchymal cells. Immunohistochemistry demonstrates that E-cadherin is abundantly localized to cell-cell connections in parent epithelial cells. In mesenchymal cells with forced E-cadherin upregulation, increased E-cadherin staining does not localize to cell-cell contacts and the cells maintain fibroblastiod morphology (Figure 5b ). In addition, mesenchymal cells with forced E-cadherin expression demonstrate no significant change in migration or invasion (Figures 5c and d) . Using the orthotopic liver tumor model, forced expression of E-cadherin in mesenchymal cells does not reduce invasion and lung metastasis, despite increased E-cadherin observed on tumor histology (Figure 5e , Table 1 , and Supplementary Figure 8) .
Knockdown of E-cadherin in mesenchymal cells treated with miR-200b and inhibitor does not restore metastatic potential In mesenchymal cells treated with miR-200b and decitabine, we utilized a stable E-cadherin short hairpin RNA (shRNA) vector to test the hypothesis that the synergistic upregulation of E-cadherin is a primary mechanism for the inhibition of metastasis. In this model, E-cadherin shRNA results in downregulation (Figures 6a and b) . This downregulation of E-cadherin is associated with increased migration and invasion in vitro (Figures 6c and d) . In vivo, targeting E-cadherin in mesenchymal cells treated with miR-200b and decitabine results in increased invasion without evidence of increasing metastatic disease (Figure 6e and Table 1 , Po0.05 comparing invasion score of mesenchymal NC-shRNA þ miR-200b þ decitabine group to mesenchymal E-cad-shRNA þ miR-200b þ decitabine group).
In Table 1 , we summarize all in vivo tumor invasion and metastasis results. We developed a scoring system (Materials and methods) to evaluate the capacity of peritoneal invasion, as the pancreas and colon are two major organs invaded by the mesenchymal cell tumors.
14 As shown in Table 1 , the invasion score equals 1.0 in all groups treated with combination of miR200b and decitabine, and the invasion score for other groups is X2.0, indicating that tumor invasion is significantly inhibited with the combination of miR-200b restoration and DNMT inhibition (Po0.01). Although targeting E-cadherin specifically in this combination miR-200b and decitabine group induces increased invasion, loss of E-cadherin does not increase metastasis.
Additional markers of the EMT/MET spectrum in liver cancer As focused E-cadherin expression does inhibit a metastatic phenotype, and as targeting E-cadherin in miR-200b and decitabine-treated cells does not re-induce a metastatic phenotype, we sought to understand alternative mechanisms driving changes in the metastatic phenotype, independent of E-cadherin. After miR-200b upregulation and decitabine treatment, Cytokeratin-19 (Krt-19) and HNF4a are both synergistically upregulated (Supplementary Figure 9) . Krt-19 is a marker of epithelial cholangiocytes and HNF4a is a marker of hepatocyte differentiation. As alterations in E-cadherin expression alone are not sufficient to directly affect the metastatic process in our model, we propose that the broader MET and differentiation effects of Figure 5 . Direct expression of E-cadherin in mesenchymal cells is not sufficient to inhibit lung metastasis. (a) E-cadherin expression was restored in mesenchymal cells post-EMT using stable expression system. High levels of E-cadherin expression are confirmed in all four stable expression pools, mesenchymal Ecad p1, p2, p3 and p4. (b) Immunofluorescence staining demonstrates that E-cadherin is localized to the cell membrane in parental epithelial cells, and E-cadherin is localized to the cytoplasm and reduced in the mesenchymal cells. In mesenchymal cells with stable E-cadherin expression, the E-cadherin staining is increased but remains in a pattern suggestive of mesenchymal cells. No difference in the capability of cell migration (c) and invasion (d) between primary mesenchymal cells and mesenchymal cells with stable E-cadherin overexpression (n ¼ 3/group, P40.05 for both migration and invasion assays). (e) Restoration of E-cadherin expression fails to inhibit tumor invasion into the pancreas (P) and colon (C) and lung metastasis (T, tumor; L, liver; arrows indicate lung metastasis, H&E stain). 
DISCUSSION
In our previous investigation, murine mesenchymal cells derived from epithelial liver tumor after EMT in vivo demonstrate invasive growth with significant metastatic potential.
14 In human HCC, growing evidence demonstrates that the acquisition of mesenchymal phenotype has an important role in tumor progression and metastatic behavior. [33] [34] [35] Thus, we hypothesized that targeting the initiation and maintenance of EMT will result in a reduction in liver tumor metastasis. In murine lung adenocarcinoma, forced expression of miR-200 blocks the capability of tumor cells to invade and metastasize. 36 In the present study, we discovered a significant loss of miR-200 in mesenchymal tumor cells, which is correlated with tumor invasion and metastasis. Although re-expression of miR-200b reduces mesenchymal cell migration and invasion in vitro, miR-200b expression in mesenchymal cells does not inhibit a metastatic phenotype in vivo. After forced expression of miR-200b was combined with DNMT inhibition in mesenchymal cells, we demonstrated that tumor invasion and metastasis capability was significantly inhibited. This finding led us to the initial conclusion that E-cadherin may have a critical role in liver tumor metastasis. However, focused re-expression of E-cadherin in mesenchymal cells failed to reduce the invasive and metastatic phenotype, implying that the effects of miR-200b and DNMT inhibition are not mediated by the direct restoration of E-cadherin.
In this study, forced expression of miR-200b does inhibit cell migration and invasion in vitro, but does not reduce metastasis in vivo. These findings are consistent with a recent work in which miR-200 expression reduces breast cancer migration and invasion in vitro and enhances metastasis by increasing colonization. 18 Thus, the therapeutic implication of miR-200 as an inhibitor of metastasis provides a classic double-edge sword. miR-200b may reverse EMT and block the tumor migration/invasion features that are characterized by a mesenchymal phenotype, but miR-200 may enhance metastatic colonization by promoting an epithelial phenotype. In current study, the rate of lung metastasis is not significantly different in mesenchymal cells treated with either miR-200b or decitabine compared with control mesenchymal cells (Table 1) , but the slight increase in metastasis indicates that MET and modest increases in E-cadherin expression may promote metastatic colonies. However, a histological analysis of lung metastases indicates that the underlying mechanism of metastatic Figure 10) . Although these findings challenge the paradigm of MET and increased E-cadherin expression as requirements for metastatic colonization, 7,37 our results are consistent with a recent investigation in breast cancer, in which E-cadherin is not essential for determining metastatic potential. 18 In epithelial cells, E-cadherin is an important cell-to-cell adhesion molecule. E-cadherin promoter methylation is reported in EMT, and in HCC, E-cadherin promoter methylation is associated with poor prognosis and metastatic disease. 32, 34 In this current work, the E-cadherin promoter is hyper-methylated in mesenchymal cells. Further investigation is needed to assess whether E-cadherin expression can be used as a marker to evaluate invasion and metastatic potential in HCC. In this study, E-cadherin expression correlates with final outcome in the combination miR-200b and decitabine treatment group, which strongly supports E-cadherin as a marker to monitor EMT/MET and tumor metastasis. However, follow-up investigations demonstrate that upregulation of E-cadherin alone in primary mesenchymal tumors is not able to reverse invasive and metastatic phenotype. In addition, although suppression of E-cadherin does increase tumor local invasion, suppression of E-cadherin is not able to induce a metastatic phenotype after treatment with miR-200b and decitabine combination. Thus, we conclude that, in our model of liver cancer EMT, E-cadherin is a marker for cell migration and tumor invasion, but E-cadherin expression is not sufficient to evaluate metastatic potential.
Correlation of additional markers of liver epithelial cells, Cytokeratin-19 (Krt-19), which is primarily expressed in cholangiocytes, and HNF4a, primarily expressed in hepatocytes, may be used as alternative markers for HCC metastasis specifically. The downregulation of HNF4a is associated with HCC progression, loss of epithelial phenotype and metastasis. 38 Forced expression of HNF4a promotes a less invasive, well-differentiated phenotype with slower growth. 39 These reports are consistent with our findings that HNF4a is downregulated in mesenchymal cells and is significantly induced after combination of miR-200b expression and DNMT inhibition. Thus, broader MET and differentiation effects of miR-200b and DNMT inhibition may inhibit metastasis in an E-cadherin-independent mechanism. In future studies, we will investigate the specific mechanisms underlying the HNF4a upregulation after combination of miR-200b restoration and DNMT inhibition, as miR-200b and DNMT inhibitors have multiple targets and can have broad effects in driving differentiation.
In conclusion, we demonstrate that targeting metastasis in liver cancer may require a combination therapy with miR-200b expression and DNMT inhibition, which is not necessarily mediated by restoration of E-cadherin expression.
MATERIALS AND METHODS
Cell culture
Parental HCC tumor cells were isolated from Pten À / À mice. We obtained two cell lines from tumor tissues after serial transplantations and termed with 'P1' and 'P2', respectively. P2 cells were mixed with epithelial and mesenchymal cell population, and these two populations were separated into pooled cell lines, named P2E epithelial cells and P2M mesenchymal cells, as described.
14 Pten À / À P2E epithelial and P2M mesenchymal cells were cultured in Dulbecco's modified Eagle medium:F12 at 1:1 medium (Mediatech, Manassas, VA, USA) supplemented with 10% fetal bovine serumFBS, as described. 14 
Antibodies and Plasmid Constructs
The polyclonal E-cadherin antibody for western blot, immunohistochemistry and immunofluorescence, and polyclonal Zeb1 antibody for western blot were purchased from Cell Signaling (Cat# 3195s and 3396s, respectively, Danvers, MA, USA), and Zeb1 antibody for immunohistochemistry and Zeb2 antibody for immunohistochemistry and western blot were purchased from Novus Biologicals (Littleton, CO, USA) with catalog numbers NBP1-05987 and NBP1-67782, respectively. Retroviral construct for mouse E-cadherin was obtained from Addgene (Cambridge, MA, USA) with product ID#18804 and was developed by the Weinberg laboratory (Cambridge, MA, USA). 40 The mouse E-cadherin shRNA (Ecad-shRNA) was developed using Invivogen (San Diego, CA, USA) psiRNA-h7SKzeo G1 vector (Cat# ksirna3-z21) by inserting a target sequence 5 0 -GGAGATGC AGAATAATTAT-3 0 to specifically knockdown mouse E-cadherin, and the psiRNA-h7SKzeo G1 empty vector was used as a NC-shRNA. pEGFP-C1-Zeb1 construct was kindly provided by Dr K Morishita from the University of Miyazaki, Japan. 41 
Animals
Nude mice were fed ad libitum (Harlan Teklad-irradiated mouse diet 7912, Madison, WI, USA) and housed in a temperature-controlled animal facility with a 12-h light/dark cycle. All procedures were in compliance with our institution's guidelines for the use of laboratory animals and approved by the Institutional Animal Care and Use Committee.
Real-time PCR for mRNA and miRNA Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA). RNA was quantified with ND-1000 spectrophotometer (Nanodrop, Wilmington, DE, USA) and cDNA was generated. Real-time PCR experiments were conducted as described previously. 42 The housekeeping gene GAPDH and b-actin were used for DDCt calculations. Relative expression was calculated for mouse E-cadherin, Zeb1, Zeb2, HNF4a and Krt-19, using assay-ondemand primer/probe sets (Applied Biosystems, Foster City, CA, USA). For miRNA real-time PCR, miRNA species were isolated using mirVara miRNA isolation kit from Applied Biosystems, and cDNA amplified using primers for U6, miR-200 family members, miR-205 and miR-16 from Applied Biosystems, and data were normalized using U6 for DDCt calculations.
Bisulfite DNA C-T conversion and bisulfite DNA sequencing Tet-on stable miRNA system Mir-X inducible pmRi-ZsGreen1 miRNA system was purchased from Clontech (Mountain View, CA, USA), and the construct expressing miR-200b was developed by PCR strategy using the following PCR primers: upstream 5 0 -TAGTTCTCGAGGATCCT ATAAGACCCCCATCCTAAT-3 0 , and downstream 5 0 -CT CCAAAGCTAAGCTTGCCTGGGTATTGTATGCAGAA-3 0 . Constructs were verified by DNA sequencing. The stable miRNA system was developed as described in the manufacturer's protocol. Pooled mesenchymal cells with stable miR-200b or miR-NC expression were isolated per manufactures instructions.
Decitabine treatment
Tumor cells were treated with either vehicle (DMSO) or d1 mM of decitabine (Sigma-Aldrich, St Louis, MO, USA) for indicated times.
Orthotopic transplantation
Five days before tumor inoculation, nude mice were fed with doxycycline chow (200 mg/kg) purchased from Bio-Serv (Frenchtown, NJ, USA). Mice were anaesthetized with 100 mg/kg of ketamine and 10 mg/kg of xylazine, and the liver was exposed through a surgical incision. In all, 3 Â 10 5 cells in 30 ml of 1:1 Matrigel:media were orthotopically inoculated. Pressure was applied to the injection site for 2 min. Abdominal wound was closed using wound clips after tumor cell injection.
Bioluminescent image collection
Nude mice were anesthetized at defined times post cell transplant, and 150 mg/kg of potassium D-luciferin (Gold Biotechnology, St Louis, MO, USA) was injected intraperitoneal injected. Ten minutes after luciferin injection, bioluminescence images were collected using a Xenogen IVIS 50 system per manufacturer's instruction.
Invasion scoring system
The pancreas and colon were each graded based on the highest extent of tumor invasion on H&E stained slides (two independent sections at different levels more than 20 mm apart/organ). Extensive invasion equals a score of 2 points; for minor invasion, the score will be 1 point; and if there is no invasion, the score will be 0. The average invasion score for each experimental group will be the total points divide the number of animals.
Microscopy
Histology images were viewed with an Olympus CKX41 microscope (Olympus, Melville, NY, USA) using Â 40 phase objective lens and ACDSee 3.1 (SR-1) software (ACD Systems, Seattle, WA, USA), and wound-healing migration images and immunofluorescent images were collected with Nikon eclipse TE2000-5 microscope (Nikon, Melville, NY, USA) using Â 4 objective lens and Â 40/0.60 Plan Fluor objective lens, respectively, and processed with MagnaFIRE SP software (Optronics, Goleta, CA, USA).
Statistical analyses
Paired two-tailed Student's t-test was used when comparing two groups. A P value o0.05 was considered statistically significant. Ordinal logistic regression was used to compare the invasion score and determine significance between treatment groups. ABBREVIATIONS DMEM, Dulbecco's modified Eagle medium; DNMT, DNA methyltransferase; EMT, epithelial-to-mesenchymal transition; FBS, fetal bovine serum; GFP, green fluorescence protein; IF, immunofluorescence; IHC, immunohistochemistry; HCC, hepatocellular carcinoma; HNF4a, Hepatocyte Nuclear Factor 4a; MET, mesenchymal-to-epithelial transition; PI3K, phosphoinositide 3-kinasePTEN, phosphatase and tensin homolog deleted on chromosome 10.
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